Arkolith/Insider Trading/ESLA/Form 4

Xu Jiandong

Chief Financial OfficerEstrella Immunopharma, Inc. (ESLA) · full profile →Form 4 · filed Aug 26, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 18, 2026Option exercise(M)100K$0.81$82K365K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 18, 2026Option exercise(M)100K——391K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-26-093698) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Estrella Immunopharma, Inc.

Build

Ask your agent about ESLA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001213900-26-093698"
Ask your agent
Use Arkolith to summarize insider buying and selling at Estrella Immunopharma, Inc.
over the last 90 days and cite the filings.